What is it?
German chamomile flower is the evidence focus
1This page centers on German chamomile flower, Matricaria chamomilla (also called Matricaria or Chamomilla recutita), used as tea or oral extract. Roman chamomile, Chamaemelum nobile, is a related species found on some labels but should not inherit German chamomile evidence.
Human findings are modest and form-specific
5The relevant human research concerns subjective sleep outcomes and generalized anxiety disorder (GAD) populations. Results cannot establish an acute nootropic, memory, focus or wakefulness effect in healthy users.
The sleep literature is positive in places, not conclusive
4The pooled subjective sleep-quality signal has important limits: studies used different populations and preparations, and most relied on questionnaires rather than objective sleep measurement. A small primary-insomnia trial found no significant sleep-diary difference from placebo.
Names, aliases and forms
Mechanisms of action
Apigenin is a marker, not a complete explanation
9Chamomile contains apigenin and other constituents. Apigenin bound a benzodiazepine site in vitro, but the same study found complex GABA effects and did not attribute its animal locomotor effect to that binding site. This does not mean chamomile tea acts like a benzodiazepine.
Potential effects and evidence map
Human evidence is limited and preparation-specific. A 2024 review of 10 studies (772 participants) found a modest improvement in subjective Pittsburgh Sleep Quality Index (PSQI) scores, with high inconsistency between studies. Sleep duration, sleep efficiency and daytime functioning did not improve. A 28-day primary-insomnia pilot found no significant sleep-diary benefit. Small older-adult and postpartum studies reported selected subjective improvements. Standardized-extract generalized anxiety disorder (GAD) trials remain preliminary and do not establish immediate calm or cognitive enhancement in healthy users.
Chamomile may modestly improve subjective sleep-quality scores in some populations, but results are heterogeneous and do not show longer sleep, better sleep efficiency, or dependable benefit for primary insomnia.
Specific standardized German chamomile extracts have preliminary human evidence for GAD symptoms over several weeks; this does not establish immediate relaxation in healthy users.
Any stress-resilience benefit is indirect and inferred from limited GAD and subjective sleep studies.
Mood findings are exploratory subgroup results within GAD research, not evidence for a standalone antidepressant or wellbeing effect.
Chamomile has no controlled human evidence for improving focus, memory, wakefulness, or productivity.
Typical dosages and timing
Two sleep studies used 200 mg or 270 mg extract twice daily for 28 days. These were specific preparations and populations, not a universal dose. Tea, dried flowers, essential oil and Roman chamomile are not dose-equivalent. The 270 mg twice-daily pilot found no significant sleep-diary benefit.
Timing & effect horizon
The featured values are research windows: a 2-week postpartum tea study, 28-day sleep-extract studies, an 8-week anxiety-extract trial and a separate 26-week randomized continuation phase in initial responders. The continuation study did not show a significant difference in its primary relapse outcome. None establishes a recommended cycle, same-day onset, peak, effect duration or whole-extract half-life.
Safety, side effects and risk profile
Drowsiness was among the most common reported adverse events in a 2025 safety review, but events were generally self-limiting and non-serious.
NCCIH reports cases involving warfarin and some liver-metabolized drugs; additive effects with sedatives are a theoretical concern.
Preliminary evidence suggests possible estrogen-like activity, but the clinical importance is uncertain.
Controlled safety evidence during pregnancy and breastfeeding is insufficient, especially for concentrated extracts and essential oils.
Trial adverse events were uncommon and mainly mild GI symptoms or drowsiness; rare case reports describe allergic reactions including anaphylaxis.
German chamomile tea, standardized extract, Roman chamomile, essential oil, topical products, and blends are not interchangeable.
Chamomile is generally well tolerated, but rare case reports describe severe allergic reactions and anaphylaxis. Risk is higher in people allergic to ragweed, chrysanthemums, marigolds, daisies, or related Asteraceae plants.
Little controlled safety information exists for pregnancy or breastfeeding. Occasional tea-like food exposure should not be assumed equivalent to concentrated oral extracts, essential oil, or high-dose multi-ingredient products.
Interactions and cautions
NCCIH describes reports involving warfarin and some medicines processed by the liver. Additive effects with sedatives are a theoretical concern. The exact species, preparation, dose and other ingredients affect the relevance of a reported interaction.
Legal and regulatory status
As of October 19, 2026, U.S. chamomile products may be sold as teas, foods or dietary supplements; dietary supplements do not undergo FDA approval before marketing. In the EU, the EMA Matricaria flower monograph covers specified traditional-use areas involving the gut, mouth/throat, skin and common cold, without a sleep, anxiety or cognition indication. National authorities assess herbal-medicine authorizations; permitted categories and claims differ by country and product format.
Practical buying and quality notes
- Check for German chamomile (Matricaria chamomilla or M. recutita), flower as the plant part, and a declared tea amount or extract ratio. Roman chamomile and essential oil have different preparation contexts. A marker such as apigenin identifies one constituent, not equivalence to an entire studied extract. Product-specific identity, purity and potency testing matter more than an unsupported equivalence claim.1
- Compare dried-flower price per gram with dried flower, extract price per declared extract amount with similar extracts, and capsule prices only after checking contents per capsule. Include delivery costs and discounts in the total. A low price per capsule does not show a low price per extract amount. Blends need separate comparison because their other ingredients can change both effects and compatibility.12
FAQ
Is chamomile a nootropic?
5Not in the direct cognitive-enhancement sense. It is better described as a traditional calming botanical with limited, mixed human evidence for subjective sleep quality and GAD symptoms.
What chamomile dose is studied?
6The dosage row summarizes sleep-extract studies. A separate 8-week generalized anxiety disorder trial used a standardized extract with gradual dose adjustment, so its findings cannot be transferred directly to tea, gummies or a different extract.
Does a longer study prove lasting benefit?
7No. A small primary-insomnia pilot had no significant sleep-diary result, and the longer anxiety continuation study did not show a significant primary relapse difference. Study duration is not an established duration of benefit.
Who should be especially careful?
1Ragweed-family allergy, prior severe allergic reactions, warfarin and other prescription combinations are distinct caution contexts. Safety information during pregnancy and breastfeeding remains limited, especially for concentrated products.
References
- National Center for Complementary and Integrative Health. Chamomile: Usefulness and Safety. Last updated November 2024. Accessed October 19, 2026.
- NCBI Taxonomy. Matricaria chamomilla, Taxonomy ID 98504. Accessed 2026-06-30.
- NCBI Taxonomy. Chamaemelum nobile, Taxonomy ID 99037. Accessed 2026-06-30.
- Kazemi A, et al. Effects of chamomile (Matricaria chamomilla L.) on sleep: A systematic review and meta-analysis of clinical trials. Complementary Therapies in Medicine. 2024;84:103071.
- Therapeutic efficacy and safety of chamomile for state anxiety, generalized anxiety disorder, insomnia, and sleep quality: a systematic review and meta-analysis of randomized trials and quasi-randomized trials. Phytotherapy Research. 2019;33(6):1604-1615.
- A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita extract therapy for generalized anxiety disorder. Journal of Clinical Psychopharmacology. 2009;29(4):378-382.
- Mao JJ, et al. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. Phytomedicine. 2016;23(14):1735-1742.
- The effects of chamomile extract on sleep quality among elderly people: A clinical trial. Complementary Therapies in Medicine. 2017;35:109-114.
- Avallone R, et al. Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochemical Pharmacology. 2000;59(11):1387-1394.
- Zick SM, et al. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. BMC Complementary and Alternative Medicine. 2011;11:78.
- Chang SM, Chen CH. Effects of an intervention with drinking chamomile tea on sleep quality and depression in sleep disturbed postnatal women: a randomized controlled trial. Journal of Advanced Nursing. 2016;72(2):306-315.
- Ostovar M, Rezaee Z, Najibi SM, Hashempur MH. Chamomile: A systematic review of adverse events. Complementary Therapies in Medicine. 2025;91:103192.
- European Medicines Agency. European Union herbal monograph on Matricaria recutita L., flos (EMA/HMPC/55843/2011). First published April 5, 2016.